by Sue Robbins | May 18, 2020 | Migraine
The FDA has approved Dr. Reddy’s Laboratories’ celecoxib oral solution (Elyxyb) for the treatment of acute migraine in adults with or without aura. Notably, the non-steroidal anti-inflammatory drug (NSAID) was given the go-ahead with a boxed warning related to a risk...
by Sue Robbins | May 3, 2020 | Migraine
Incorporation of remote electrical neuromodulation (REN) into usual care reduced migraineurs’ use of acute migraine medication, potentially decreasing the risk of medication overuse headache (MOH), according to a study published in Frontiers in Neurology. REN is a...
by Sue Robbins | Jan 27, 2020 | Migraine
Treatment with the orally administered, small-molecule calcitonin gene-related peptide receptor antagonist ubrogepant in patients with acute migraine has been associated with freedom from pain and the absence of the patient-determined most troublesome symptom compared...
by Sue Robbins | Dec 26, 2019 | Migraine
The FDA has approved ubrogepant (Ubrelvy; Allergan) for the acute treatment of migraine with or without aura in adults, making it the first-in-class oral calcitonin gene-related peptide (CGRP) antagonist for this indication.1 The new drug application (NDA) was...
by Sue Robbins | Dec 9, 2019 | Migraine
Aspirin, in high doses from 900 to 1300 mg, was shown to be an effective and safe treatment option for acute migraine headaches, with further research showing its potential efficacy in preventing recurrent migraine headaches through lower doses of 81 to 325 mg,...
